KRAS Mutations: An Old Oncogene Becomes a New Predictive Biomarker
作者： Gregory J. Riely , Marc Ladanyi
DOI: 10.2353/JMOLDX.2008.080105
关键词:
摘要: This commentary highlights a novel assay for detection of mutations in KRAS, which have recently emerged as useful negative predictive biomarker.
jmdjournal.org
unirioja.es参考文章(28)
Allan R. Li, Dhananjay Chitale, Gregory J. Riely, William Pao, Vincent A. Miller, Maureen F. Zakowski, Valerie Rusch, Mark G. Kris, Marc Ladanyi, EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression The Journal of Molecular Diagnostics. ,vol. 10, pp. 242- 248 ,(2008) , 10.2353/JMOLDX.2008.070178
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
William Pao, Marc Ladanyi, Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clinical Cancer Research. ,vol. 13, pp. 4954- 4955 ,(2007) , 10.1158/1078-0432.CCR-07-1387
Marc Ladanyi, William Pao, Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern Pathology. ,vol. 21, ,(2008) , 10.1038/MODPATHOL.3801018
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Jenifer L. Marks, Yixuan Gong, Dhananjay Chitale, Ben Golas, Michael D. McLellan, Yumi Kasai, Li Ding, Elaine R. Mardis, Richard K. Wilson, David Solit, Ross Levine, Kathrin Michel, Roman K. Thomas, Valerie W. Rusch, Marc Ladanyi, William Pao, Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma Cancer Research. ,vol. 68, pp. 5524- 5528 ,(2008) , 10.1158/0008-5472.CAN-08-0099
Lecia V. Sequist, Daphne W. Bell, Thomas J. Lynch, Daniel A. Haber, Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 25, pp. 587- 595 ,(2007) , 10.1200/JCO.2006.07.3585
Vincent A. Miller, Gregory J. Riely, Maureen F. Zakowski, Allan R. Li, Jyoti D. Patel, Robert T. Heelan, Mark G. Kris, Alan B. Sandler, David P. Carbone, Anne Tsao, Roy S. Herbst, Glenn Heller, Marc Ladanyi, William Pao, David H. Johnson, Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib Journal of Clinical Oncology. ,vol. 26, pp. 1472- 1478 ,(2008) , 10.1200/JCO.2007.13.0062
Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, Rafael G. Amado, Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 25, pp. 1658- 1664 ,(2007) , 10.1200/JCO.2006.08.1620
W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Annals of Oncology. ,vol. 19, pp. 508- 515 ,(2008) , 10.1093/ANNONC/MDM496